Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Objective To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment.Methods Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies. Serum levels of acute phase reactants C reactive pro...

Full description

Bibliographic Details
Main Authors: Kristen Sweet, Matthew J Loza, Philip Cooper, Qingxuan Song, Keying Ma, Karen Leander, Vani Lakshminarayanan, Carol Franks
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/7/2/e001679.full

Internet

https://rmdopen.bmj.com/content/7/2/e001679.full

Similar Items